The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study

被引:6
|
作者
Talks, S. James [1 ]
Daien, Vincent [2 ]
Mitchell, Paul [3 ]
Aslam, Tariq [4 ,5 ]
Barratt, Jane [6 ]
Biberger, Anna [7 ]
Lamoureux, Ecosse L. [8 ,9 ]
Hirst, Ceri [10 ]
Sylvanowicz, Michelle [10 ]
Finger, Robert P. [11 ]
机构
[1] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle Eye Ctr, Newcastle Upon Tyne, England
[2] Univ Hosp Montpellier, Dept Ophthalmol, Montpellier, France
[3] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia
[4] Manchester Royal Eye Hosp, Manchester, England
[5] Univ Manchester, Manchester, England
[6] Int Federat Ageing, Toronto, ON, Canada
[7] Cerner Enviza, Munich, Germany
[8] Singapore Eye Res Inst, Singapore, Singapore
[9] Duke NUS Med Sch, Singapore, Singapore
[10] Bayer Consumer Care AG, Basel, Switzerland
[11] Univ Bonn, Dept Ophthalmol, Bonn, Germany
关键词
nAMD; Anti-VEGF; Patient care; Communication; Adherence; Persistence; Emotion; ANTI-VEGF TREATMENT; GROWTH-FACTOR THERAPY; DEPRESSION; EXPERIENCE; OUTCOMES; ANXIETY;
D O I
10.1007/s40123-022-00631-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction: Visual impairment resulting from diseases such as neovascular age-related macular degeneration (nAMD) may cause behavioural, environmental, psychological, and logistical challenges that could act as barriers to effective uptake and sustainability of treatment with anti-vascular endothelial growth factor agents (anti-VEGFs). Understanding emotions and experiences of patients with nAMD may help inform the determinants of adherence, and could contribute to improvements in ophthalmic outcomes and quality of life. Methods: Seventeen patients with nAMD receiving anti-VEGF injections were enrolled from three clinics: one each in France (n = 5), Germany (n = 6), and the UK (n = 6). Patients' health information and treatment characteristics were collected. Individual phone interviews were conducted by experienced health care interviewers. Transcripts were analysed thematically. Results: Patients (53% female) had a mean age of 77 years. Bilateral anti-VEGF injections were received by 24% (n = 4); and most (76%, n = 13) were adherent to their treatment. Patient emotions at diagnosis ranged from happiness at learning about the treatment for nAMD to being terrified of receiving an injection in the eye. Most patients mentioned feeling anxious and fearful before their first injection despite receiving reassurance. After the first injection, these feelings and apprehension abated for many, but not all. With the goal of maintaining the best possible vision, few (24%, n = 4) patients reported more than one missed appointment, and most had never considered stopping treatment. No patient reported additional assistance beyond family support; however, many had difficulties with recreational and domestic activities and had developed coping strategies. Conclusion: This study provides insights on patients' emotions related to their experience of nAMD and its management, highlighting the varying experiences between individuals. It shows the importance of the patient's voice when considering patient care and management, and how the nature and timing of interventions can improve the experience of living with and managing nAMD.
引用
收藏
页码:561 / 575
页数:15
相关论文
共 50 条
  • [41] Preferred therapies for neovascular age-related macular degeneration
    Chiang, Allen
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 199 - 204
  • [42] Bevacizumab for Neovascular Age-related Macular Degeneration in China
    Li, Xiaoxin
    Hu, Yonghua
    Sun, Xiaodong
    Zhang, Junjun
    Zhang, Maonian
    OPHTHALMOLOGY, 2012, 119 (10) : 2087 - 2093
  • [43] Laser photocoagulation for neovascular age-related macular degeneration
    Virgili, G.
    Bini, A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [44] Proteomics of vitreous in neovascular age-related macular degeneration
    Nobl, Matthias
    Reich, Michael
    Dacheva, Ivanka
    Siwy, Justyna
    Mullen, William
    Schanstra, Joost P.
    Choi, Chul Young
    Kopitz, Jurgen
    Kretz, Florian T. A.
    Auffarth, Gerd U.
    Koch, Frank
    Koss, Michael J.
    EXPERIMENTAL EYE RESEARCH, 2016, 146 : 107 - 117
  • [45] Preferred therapies for neovascular age-related macular degeneration
    Lally, David R.
    Gerstenblith, Adam T.
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (03) : 182 - 188
  • [46] Guidance for the treatment of neovascular age-related macular degeneration
    Schmidt-Erfurth, Ursula M.
    Richard, Gisbert
    Augustin, Albert
    Aylward, William G.
    Bandello, Francesco
    Corcostegui, Borja
    Cunha-Vaz, Jose
    Gaudric, Alain
    Leys, Anita
    Schlingemann, Rainier O.
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2007, 85 (05): : 486 - 494
  • [47] Systemic Changes in Neovascular Age-Related Macular Degeneration
    Singh, Amardeep
    DANISH MEDICAL JOURNAL, 2014, 61 (06):
  • [48] Abicipar pegol for neovascular age-related macular degeneration
    Hussain, Rehan M.
    Weng, Christina Y.
    Wykoff, Charles C.
    Gandhi, Raya A.
    Hariprasad, Seenu M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (09) : 999 - 1007
  • [49] The molecular mechanisms of neovascular age-related macular degeneration
    Miller, DW
    Joussen, AM
    Holz, FG
    OPHTHALMOLOGE, 2003, 100 (02): : 92 - 96
  • [50] Ranibizumab for neovascular age-related macular degeneration - Reply
    Rosenfeld, Philip J.
    Brown, David M.
    Schneider, Susan
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 749 - 750